Spero Therapeutics (NASDAQ:SPRO) posted its quarterly earnings results on Thursday. The company reported ($0.60) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.75) by $0.15, Fidelity Earnings reports. The business had revenue of $1.69 million during the quarter, compared to the consensus estimate of $0.84 million. Spero Therapeutics had a negative return on equity of 52.22% and a negative net margin of 1,402.91%.
Spero Therapeutics stock opened at $12.98 on Friday. Spero Therapeutics has a 12-month low of $5.52 and a 12-month high of $19.00. The stock has a market capitalization of $223.33 million, a price-to-earnings ratio of -0.73 and a beta of 2.96.
A number of research analysts recently commented on the company. Oppenheimer set a $30.00 price target on Spero Therapeutics and gave the company a “buy” rating in a research note on Tuesday, February 26th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Spero Therapeutics in a research note on Tuesday, February 26th. Zacks Investment Research downgraded Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 18th. Finally, ValuEngine downgraded Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.65.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Read More: Trading Ex-Dividend
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.